Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The DARE train has not even left the station... gathering up steam...
I hope everyone loaded up Monday...
Monday, Jan 23, is the day...
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.
https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.
Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.
By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18
Nice chunk of change so far...
Since my call
Jan 03, 2023 9:29 AM
$DARE It has begun...
DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11
UM...AH... looks like a winner already...
and it has not even started!
BUT...
I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.
DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.
Good fortune to all (except shorts, who bet wrong on this leg up).
Just a little bit of DD will prove you wrong.
Hop aboard, this is just the beginning!
DARE up over 30% already this year.
Up 20% in 2 days
UP 10% since yesterday morning.
Karma, Steiner... KARMA!!
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
Key Words "Real Drugs".
Q4 will be interesting
Steiner cost me BIG BUCK$$$$$
with his BIG LIE on Cramers Show.
I could never trust him again!!
I see YOU TUBE took the video of the show private.
The snake most likely got to the guy who made it!
OH OH
Doubts arising?
WOW!! Nice EOD catapult!!
https://charts.stocktwits.com/production/original_483459038.png
Too high a mortality rate in the placebo group?
Not enough participants in the study?
Location... location... location...
Some report that the clinics in the study did not even have a waiting room...
HMMMMMMMMMMMMMMMMMMMMMMMMMMMMM
Another week... another wait...
ZZZZZZZZZZZZZZZZZZZZZZ
Steiner better get his offering out there before the SP goes down any further.
At least one director was smart enough to sell...
It would be just like him to pull a fast one right now, before it falls too far down the hill....
*SNIFF* *SNIFF*
Does Steiner have another offering in the works?
"risks related to our ability to obtain sufficient financing on acceptable terms when needed to fund product development and our operations, including our ability to secure timely grant or other funding to develop, manufacture or distribute sabizabulin as a potential COVID-19 treatment"
(from today's report)
Something is down...
Being played
Something is up...
YES!
Doesn't look good...
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
Moving closer to gaps...
This could become interesting...
This DARE stock will drive a sane man crazy!
Waiting for the inevitable...
Just a few more days...
CFO got his 100K SH
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
Main catalyst coming soon: FDA approval of NDE for Ovaprene, non hormonal birth control product. The company already in partnership with Bayer and NIH on this.
$1B
market. NDE approval will trigger the start of a pivotal Ph3 trial this year. Hopefully, their second FDA-approved product by next year. The trial will only cost them $5, and they get a bonus check from Bayer
$20M
on start.
Other pipeline catalysts soon:
1)Xaciato marketing/sales/revenue by Q4 or earlier.
2) VVA-1 Ph2 data: Q3
3) Sildenafil Ph2 data: Q3